56 results about "Human rotavirus" patented technology

The invention relates to human rotavirus Delta VP8* subunit recombinant protein and application thereof. The human rotavirus Delta VP8* subunit recombinant protein comprises a T cell epitope P2 in tetanus toxin and a rotavirus Delta VP8* subunit. By the recombinant protein disclosed by the invention, the immune efficacy of a Delta VP8* subunit vaccine can be greatly improved; faster and stronger neutralization antibody titer can be induced; moreover, anti-p[4] genotype specific rotavirus cross neutralization antibody of high titer can be induced; simultaneously, the potential risk of inducing intussusception by taking attenuated rotavirus vaccine orally can be overcome; therefore, the recombinant protein is applicable to preparing a rotavirus vaccine.

The invention discloses a human rotavirus strain. The human rotavirus strain is characterized in that the strain is a Rotavirus A ZTR-5 strain, and is collected to CGMCC (China General Microbiological Culture Collection Center of Microbiological Culture Management Committee) on 27th, June 2011, and the number is CGMCCNo.4977. The strain is a wild type single purified strain of human rotaviruses, and is strong in virus replication capability and good in genetic stability; and the virus seed can be applied as a production virus seed for developing human rotavirus vaccines, and is applicable to attenuated type rotavirus oral vaccines and inactivated human rotavirus inject vaccines. The invention provides a separation, culture and identification method of the human rotavirus strain.

The present invention provides vaccine compositions of attenuated human rotavirus. More particularly, the attenuated human rotavirus is produced by cold passage and thus contains attenuating mutations which produce virus having a cold-adapted (ca) and temperature sensitive (ts) phenotype. The attenuated strains are used in methods for stimulating the immune system of an individual to induce protection against human rotavirus by administration of the ca attenuated rotavirus.

The invention provides a human rotavirus VP8 recombinant protein. The amino acid sequences of the VP8 recombinant protein include an amino acid sequence of a human rotavirus VP8 protein (hereinafter referred to as VP8 protein) and an amino acid sequence of exogenous polypeptide. The isoelectric point of the exogenous polypeptide is less than or equal to 5. The invention also provides a human rotavirus vaccine prepared based on the VP8 recombinant protein. Compared with the prior art, the VP8 recombinant protein provided by the invention can be expressed by fusing the VP8 protein with negativecharge-containing amino acid polypeptide fragments in tetanus toxin and/or diphtheria toxin proteins, and the water solubility and yield of the rotavirus VP8 protein expressed by escherichia coli areimproved; and moreover, the obtained fused protein has good immune ability, and the prepared vaccine has good effect.

The present invention provides vaccine compositions for protection against human rotaviral disease designed for use in particular areas of the world. Human×bovine reassortant rotavirus comprising each of the four clinically most important VP7 serotypes of human rotavirus are combined with other VP7 serotypes typically found in the area of interest into a multivalent formulation which provides a high degree of infectivity and immunogenicity. Methods and an administration protocol for producing an immunogenic response without producing an increased risk of intussusception are also provided.

The invention discloses a chicken egg yolk antibody resisting human A rotavirus as well as a preparation method and application thereof. The method comprises steps of expressing and purifying structural protein VP7 or VP8 of human rotavirus in vitro, immunizing laying hens, collecting eggs, and separating and purifying egg yolk antibody of VP7 or VP8. The prepared chicken egg yolk antibody can be freeze dried and prepared into antibody dry powder for preventing and treating rotavirus. The preparation method has the beneficial effects that a large quantity of VP7 and VP8 antigens are expressed and recombined in vitro by a genetic engineering technology, the benefits are high, the cost is low, small field is required, and the method is environment-friendly; the potential risk of scattering virus caused by inactivation by rotavirus or attenuated vaccine in the traditional preparation process of egg yolk antibody is avoided, and the method meets the requirement of animal welfare. The egg yolk antibody prepared by the method can be prepared into oral antibody dry powder biological agent after sterility test, has obvious effect in treating rotavirus infectious diarrhea, takes effect rapidly and has low cost, and the prevention rate reaches over 95%.

The membrane chip for simultaneous detection of three groups, A, B and C, of human rotaviruses includes positively charged nylon membrane, and dotted coating with oligonucleotide probes, contrasts and blanks distributed in array on glass substrate. The dotted coating has 6 specific detecting probes of different groups of human rotaviruses, 1 positive contrast probe with digoxin marker in its 5í» end, and 4 negative contrast probes and blank sample applying liquid contrast. The present invention also discloses the preparation process and application as clinical diagnosis reagent of the chip. The chip of the present invention operates in multiple PCR amplification mode to make the detected nucleic acid carry digoxin marker and obtain hybridized result through immunological coloration, can complete gene detection and group identification of several groups of human rotaviruses, and has wide application foreground in food detection, disease prevention and clinical application.

Provided are G12 human rotaviruses having VP7 gene of SEQ ID NO: 1 or 2 and VP4 gene of SEQ ID NO: 3 or 4; antibodies specific for said rotaviruses; and a vaccine composition containing the same. The antibodies and the vaccine composition are effective for diagnosing rotavirus infection and for treatment of diseases caused by rotavirus.

The invention relates to a recombinant bifidobacterium hRV-VP7 expression vector and the oral vaccine. The invention pertains to the field of genetic engineering. The technical problem to be solved is to construct a new bifidobacterium expression vector of hRV virus VP7 protein. The recombinant bifidobacterium hRV-VP7 expression vector of the invention is loaded with a virus protein VP7 coding gene sequence of a human group A rotavirus. The expression vector of the invention can be transfected into the bifidobacterium and can be further prepared into an hRV/VP7 transgenic bifidobacterium-hRV-VP7 recombinant vector oral live vaccine preparation after fermentation culture. The invention is mainly used for the prevention and adjuvant treatment of infantile diarrhea which is caused by human rotavirus, thus having great market prospect.

A vaccine composition and method of vaccination are provided useful for immunizing a subject against a rotavirus. The vaccines include rotavirus strains CDC-9 and CDC-66, fragments thereof, homologues thereof, or combinations thereof. Inventive vaccines may include a fragment of CDC-9, CDC-66, homologues thereof, or combinations thereof. Methods of inducing an immunological response are provided by administering an inventive vaccine.

The invention provides a primer probe group, a kit and a method for detecting G II type norovirus, and belongs to the technical field of norovirus detection. The primer probe group comprises an upstream primer NVF6, a downstream primer NVR6 and a fluorescent probe NVP9, wherein the nucleotide sequence of the upstream primer NVF6 is shown as SEQ ID No. 1; the nucleotide sequence of the downstream primer NVR6 is shown as SEQ ID No. 2; and the nucleotide sequence of the fluorescent probe NVP9 is shown as SEQ ID No. 3. The primer probe group provided by the invention can be used for specifically detecting G II type norovirus including G II. 4, G II. 3, G II. 6 and G II. 17, and has no cross reaction with astrovirus, MS2 bacteriophage, human rotavirus and human adenovirus. The primer probe group for detecting G II type norovirus provided by the invention is high in sensitivity, and the lowest detection limit is 1.22 copies/microliter.

The invention discloses a human rotavirus vaccine. The human rotavirus vaccine is a combined vaccine which is formed by polyvalent pneumococcal polysaccharide and two or more than two of carrier proteins by virtue of connectors, wherein the connectors are magnetic nano-microspheres; one of the carrier proteins is a rotavirus protein. A preparation method of the human rotavirus vaccine comprises a step of respectively coupling the polyvalent pneumococcal polysaccharide and two or more than two of carrier proteins (one of the carrier proteins is the rotavirus protein) with the magnetic nano-microspheres. The human rotavirus vaccine is simple in preparation process; by adopting the human rotavirus vaccine using the nano-microspheres as the connector, the mice Th1-type immune response, and the immune persistence, specificity and affinity of the polysaccharide specific antibody can be increased; in addition, the mice can be induced so as to produce rotavirus antibodies; the human rotavirus vaccine has the prevention effect of two vaccines; therefore, the human rotavirus vaccine has very wide application prospect.

A transgenic plant able to express the coat protein of humanized rotavirus, its preparing process, and its application for preventing infantile diarrhea are disclosed.

The invention relates to a preparation method of multivalence egg-yolk immunoglobulin for resisting diarrheas, comprising the following steps of: (1) laying hen immunization: simultaneously immunizing laying hens by using a vaccine prepared from Escherichia coli and human rotaviruses in an immunology method; and (2) separation and purification of the multivalence egg-yolk immunoglobulin for resisting the diarrheas: degreasing the yolks of eggs collected in the step (1) in a water dilution method to obtain a multivalence egg-yolk immunoglobulin solution with the function of diarrhea resistance, concentrating the solution by 4-8 times by using 5 thousand membranes, then salting out the concentrated solution at the ammonium sulfate saturation of 45%-50% and the pH value of 6.0-7.0, sequentially ultrafitering the dissolved sediment by using 50 thousand membranes and 5 thousand membrane, carrying out chromatographic treatment to the salted and ultrafiltered product and then further purifying the product to obtain the multivalence egg-yolk immunoglobulin. Compared with the prior art, the preparation method has the advantages of low cost, high yield, wide application range and the like.

The invention discloses an application of lactoferrin in the drug to prevent human rotavirus, which is characterized by the following: the medium effective dose of lactoferrin is 278. 45+-12. 88mu g/mL; the medical treating index is 17. 98; the resource is wide and the cost is inexpensive, which can prevent HRV, therefore paving basis for new drug sieving.

The invention provides an inactivated vaccine for a human rotavirus, wherein the vaccine contains capsid protein produced from cracking of rotavirus totivirus particles, and the viral protein in each dose of the inactivated vaccine for the human rotavirus is 100-200 [mu]g, and the aluminum phosphate adjuvant is 0.5 mg per dose. Compared with an existing virus purification stoste, the impure protein in the inactivated vaccine for the human rotavirus is greatly reduced, and the rotavirus vaccine has higher immunogenicity and potency, is safer to use and is more applicable to large-scale production.